| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041268147 |
| P356 | DOI | 10.1038/CLPT.2009.72 |
| P698 | PubMed publication ID | 19458613 |
| P5875 | ResearchGate publication ID | 24442817 |
| P2093 | author name string | D Frank | |
| D Lütjohann | |||
| A Jetter | |||
| O Doroshyenko | |||
| U Fuhr | |||
| D Tomalik-Scharte | |||
| P2860 | cites work | Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations | Q47850259 |
| Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns | Q48698266 | ||
| Chronopharmacokinetic study with prolonged infusion of midazolam. | Q50804443 | ||
| The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. | Q50867766 | ||
| Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. | Q51438639 | ||
| Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. | Q51817870 | ||
| Physiologic and temporal variation in hepatic elimination of midazolam. | Q51860544 | ||
| Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin | Q57825152 | ||
| Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes | Q33914036 | ||
| Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals | Q35579020 | ||
| Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities | Q36641870 | ||
| Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance | Q36641884 | ||
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach | Q36720920 | ||
| Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy | Q36729155 | ||
| High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. | Q40541341 | ||
| Metabolism of 4 beta -hydroxycholesterol in humans. | Q40723392 | ||
| Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 | ||
| 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin | Q43146767 | ||
| 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians | Q43944775 | ||
| Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats | Q44447128 | ||
| Metabolism and elimination of quinine in healthy volunteers | Q44550877 | ||
| In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam | Q45095095 | ||
| Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil | Q45249932 | ||
| There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found | Q46430562 | ||
| No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam | Q46512594 | ||
| CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition | Q46580820 | ||
| CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels | Q46610452 | ||
| Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients | Q46816943 | ||
| Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity | Q46856522 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | 4β-hydroxycholesterol | Q27158713 |
| P304 | page(s) | 147-153 | |
| P577 | publication date | 2009-05-20 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | |
| P478 | volume | 86 |
| Q46220508 | 2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers). |
| Q37700667 | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State |
| Q47702408 | 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients |
| Q34580565 | 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans |
| Q36072512 | 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes |
| Q36802040 | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? |
| Q39800984 | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects |
| Q42873293 | Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan |
| Q104489706 | Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases |
| Q38763583 | CYP3A activity: towards dose adaptation to the individual. |
| Q38903289 | CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease |
| Q47400761 | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
| Q33870649 | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin |
| Q51732246 | Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. |
| Q97527724 | Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A |
| Q47759066 | Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females |
| Q43144692 | Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? |
| Q90291534 | Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers |
| Q58751507 | Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients |
| Q41556479 | Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model |
| Q88635860 | Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker |
| Q47917564 | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration |
| Q99711636 | Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans |
| Q88464210 | Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker |
| Q35135974 | Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. |
| Q38813488 | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. |
| Q41328717 | Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects |
| Q58003103 | Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians |
| Q37076544 | Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation |
| Q38986439 | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
| Q44716047 | The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro |
| Q90012005 | Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes |
| Q34570949 | Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects |
| Q49720145 | Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity? |
Search more.